Clinical bottom line
Chronic pruritic lichen planus (LP) remains a therapeutic challenge due to its relapsing course and limited high-quality evidence guiding systemic treatment. Emerging systemic therapies, including immunomodulators and targeted agents, show promise in reducing pruritus and lesion severity, but current data are largely from small case series and expert reviews rather than large randomized controlled trials. Corticosteroids remain the mainstay systemic option, with newer agents under investigation to improve efficacy and safety profiles. Clinicians should individualize treatment, balancing symptom control against potential adverse effects, and remain alert to evolving evidence.
What the evidence shows
Lichen planus is a chronic inflammatory disorder characterized by T-cell mediated interface dermatitis, often presenting with intensely pruritic, violaceous papules and plaques (Rebora et al., 2015). Systemic corticosteroids have long been the cornerstone of treatment for widespread or refractory LP, providing rapid symptom relief but associated with relapse upon tapering and systemic side effects (Sardana et al., 2013). Alternative systemic agents such as retinoids, immunosuppressants (e.g., azathioprine, mycophenolate mofetil), and antimalarials have been used with variable success, though high-quality comparative data are lacking (Sardana et al., 2013; Rebora et al., 2015).
Recent interest has focused on targeted immunomodulatory therapies. For example, topical corticosteroid delivery innovations, such as mucoadhesive clobetasol patches, have demonstrated efficacy in erosive oral LP, improving local drug retention and reducing systemic exposure (Decision letter, 2021). Although these data pertain to oral LP, they highlight the potential for novel delivery systems to enhance treatment tolerability.
The immunopathogenesis of LP involves a predominance of cytotoxic CD8+ T lymphocytes and a pro-inflammatory cytokine milieu, suggesting that agents modulating T-cell activity or cytokine signaling could be beneficial (Rebora et al., 2015). However, robust clinical trials evaluating biologics or small molecule inhibitors in chronic pruritic LP are currently lacking, representing a significant evidence gap.
Chronic hepatitis C infection is a recognized trigger for eruptive lichen planus, often with severe pruritus, and antiviral treatment may lead to LP improvement, underscoring the importance of identifying and managing underlying etiologies (Beck et al., 2020).
Caveats and uncertainty
The evidence base for systemic treatments in chronic pruritic LP is limited by small sample sizes, heterogeneous patient populations, and a paucity of randomized controlled trials. Most data derive from observational studies, expert opinion, and older literature, with few recent large-scale trials to guide practice (Sardana et al., 2013; Rebora et al., 2015). The heterogeneity of LP subtypes and variable clinical presentations complicate treatment standardization.
Safety profiles of systemic immunosuppressants require careful consideration, particularly in elderly patients or those with comorbidities. The long-term safety and efficacy of novel systemic agents remain unestablished. Additionally, the role of emerging topical formulations and their systemic absorption is incompletely characterized.
The immunological complexity of LP suggests that corticosteroid responsiveness may vary depending on lymphocyte infiltration patterns, as suggested by recent immunopathological reviews, which may inform future personalized treatment approaches (Review, 2025).
How this may change practice
Clinicians managing chronic pruritic LP should continue to prioritize systemic corticosteroids for severe or widespread disease while recognizing their limitations. Consideration of alternative systemic agents may be warranted in refractory cases, guided by patient comorbidities and tolerability.
Emerging topical delivery systems, such as mucoadhesive corticosteroid patches, may offer improved local control with reduced systemic exposure, particularly in oral LP, and warrant consideration as adjunctive therapy.
Identification and treatment of underlying triggers, including hepatitis C virus infection, remain critical components of comprehensive management.
Ongoing research into the immunopathogenesis of LP may soon enable more targeted systemic therapies, emphasizing the need for clinicians to stay abreast of evolving evidence and clinical trial data.